GT Biopharma (GTBP)

GT Biopharma (GTBP) Income Statement


GT Biopharma Income Statement

Last quarter (Q2 2023), GT Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, GT Biopharma's net income was $-1.99M. See GT Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
---$ 0.00$ 0.00$ 0.00
Cost of Revenue
Gross Profit
Operating Expense
$ -29.76M$ 21.26M$ 57.52M$ 6.76M$ 11.46M$ 21.55M
Operating Income
$ -12.76M$ -21.26M$ -57.52M$ -6.76M$ -11.46M$ -21.55M
Net Non Operating Interest Income Expense
$ 597.00K$ 284.00K$ -680.00K$ -3.32M$ -2.13M$ -9.12M
Other Income Expense
$ 2.12M$ -89.00K$ -182.00K$ -18.21M$ -25.06M$ -228.51M
Pretax Income
$ -14.21M$ -20.88M$ -58.01M$ -28.30M$ -38.65M$ -259.19M
Tax Provision
----$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
-$ 119.00K----
Net Income Common Stockholders
$ -14.21M$ -20.88M$ -58.01M$ -28.30M$ -38.65M$ -259.19M
Basic EPS
$ -0.45$ -0.66$ -2.06$ -6.45$ -11.39$ -87.72
Diluted EPS
$ -0.28$ -0.66$ -2.06$ -6.45$ -11.39$ -87.72
Basic Average Shares
$ 142.51M$ 31.87M$ 28.16M$ 4.39M$ 3.38M$ 2.96M
Diluted Average Shares
$ 110.64M$ 31.87M$ 28.16M$ 4.39M$ 3.38M$ 2.96M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ -29.76M$ 21.26M$ 57.52M$ 6.76M$ 11.46M$ 21.55M
Net Income From Continuing And Discontinued Operation
$ -14.68M$ -20.90M$ -58.01M$ -28.30M$ -38.65M$ -259.19M
Normalized Income
$ -8.49M--$ -22.68M$ -13.59M$ -30.67M
Interest Expense
---$ 3.32M$ 2.13M$ 9.12M
$ -14.70M$ -20.88M$ -57.33M$ -24.98M$ -36.52M$ -250.07M
$ -12.65M$ -20.78M$ -57.33M$ -24.98M$ -36.52M$ -250.06M
Currency in USD

GT Biopharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis